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RESULTS During a median follow-up of 1808 days HLA antibodies were detected in 106 of 238 eligible
patients (44%). Out of these, 73 patients (69%) had DSA and 33 patients (31%) had NonDSA only.
Medium-term allograft function, as determined by eGFR slope over three years, improved in patients
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a b s t r a c t
Background: Donor-specific antibodies are associated with high immunological risk and poor allograft
outcome. Risk and clinical relevance of non-donor-specific HLA antibodies is less clear.
Methods: A retrospective single-center study was conducted in all patients receiving a first kidney trans-
plant at the University hospital of Zürich between 01/2006 and 02/2015. Patients were stratified into 3
groups having either no HLA antibodies at all (NoAB), HLA antibodies with donor specificity (DSA) and
HLA antibodies without donor specificity (NonDSA). Allograft outcome was assessed using the slope of
the estimated glomerular filtration rate (eGFR slope) starting at 12 months after transplantation.
Results: During a median follow-up of 1808 days HLA antibodies were detected in 106 of 238 eligible
patients (44%). Out of these, 73 patients (69%) had DSA and 33 patients (31%) had NonDSA only.
Medium-term allograft function, as determined by eGFR slope over three years, improved in patients
with NoAB (months 12–48: +0.7 ml/min/1.73 m2) but deteriorated significantly in patients with both
DSA (months 12–48: 1.5 ml/min per1.73 m2/year, p = 0.015) and NonDSA (months 12–48: 1.8 ml/
min per1.73 m2/year, p = 0.03) as compared to the group with NoAB.
Conclusion: Both, donor-specific and non-donor-specific HLA antibodies are associated with medium-
term kidney allograft dysfunction as compared to patients with no HLA antibodies.
 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
1. Introduction
Current short-term kidney allograft survival is outstanding,
however, long-term allograft survival remains suboptimal. Chronic
allograft injury, associated with progressive fibrosis and declining
renal function, is the major cause of long-term allograft loss. Both
immunologic and non-immunologic processes contribute to allo-
graft injury, yet the underlying mechanisms are not completely
understood [1]. Early identification of patients at risk of graft loss
would be desirable, to allow early intervention and to predict graft
survival. Detection of donor-specific HLA antibodies (DSA) has
been a major focus of study and DSA are an established biomarker
associated with deterioration in allograft function [2,3]. Develop-
ment of DSA is associated with antibody-mediated rejection
(ABMR) as most important cause for late graft loss [1,2,4–7].
Patients with pre-formed DSA are known to be at increased risk
of early graft failure [8]. Importantly, de novo DSA develop in 11%
of transplant patients by year 1 post-transplantation and 30% by
year 10 post-transplantation, and are also associated with poorer
transplant outcomes [9,10]. Thus, routine screening for occurrence
of DSA by single antigen beads such as the Luminex single antigen
bead (SAB) assay is recommended [11,12]. With the currently
available Luminex SAB assays for detection of DSA, a considerable
number of patients also show non-donor-specific HLA antibodies
(NonDSA). The clinical relevance of NonDSA is less clear. The sem-
inal paper by Opelz, et al. [13] showed that even in HLA-identical
siblings, the presence of panel-reactive antibodies (PRA) against
HLA antigens before transplantation was associated with reduced
graft survival beyond the first year, suggesting that NonDSA play
a role in late allograft failure. Likewise, further studies observed
a negative impact of pre-transplant NonDSA on graft survival
[13–15]. Similar observations were also reported for detection of
NonDSA post-transplantation [16,17]. In contrast, other groups
have reported, that pre-transplant sensitization per se is not
https://doi.org/10.1016/j.humimm.2020.10.010
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associated with increased immunological risk of graft loss except if
DSA are present [15,18,19]. Hence, findings regarding this clinically
highly relevant question of immunological risk associated with
NonDSA on allograft outcome are controversial.
In this study, we aim to investigate the impact of pre- and post-
transplant NonDSA on allograft function. Most prior studies either
compared graft survival between different groups stratified by
their pre-transplantation antibody profile [13–15,18] or applied a
cross-sectional design comparing graft loss or glomerular filtration
rate at a given time point depending on presence or absence of HLA
antibodies[16,17]. Here, we analyzed the longitudinal eGFR slope
as surrogate marker for long-term kidney function [20–23] in rela-
tion to the presence or absence of HLA antibodies as detected by
Luminex assay.
2. Patients and Methods
2.1. Study design and patient population
In this single-center retrospective cohort study, all adult kidney
allograft recipients receiving their first transplant between January
2006 and February 2015 at the University hospital of Zürich were
included with a maximum period of observation for kidney func-
tion till February 2016. Recipients younger than 18 years of age,
or multi-organ transplantations, as well as patients with prior kid-
ney transplantation and ABO incompatible kidney transplantations
were excluded. The study was approved by the local Ethics com-
mittee of Zürich (Basec number: 2017–00500) and performed in
adherence to the declaration of Helsinki and the Declaration of
Istanbul on Organ-Trafficking and Transplant-Tourism.
2.2. Patient follow-up and immunosuppression
All kidney transplant recipients are seen at least annually at our
center. In case of graft dysfunction or other complications, patients
are referred earlier for follow-up. Immunosuppressive regimens
follow our internal guidelines: Induction therapy with T-cell
depleting agents (Thymoglobulin) is given to patients with pre-
formed DSA, interleukin 2 receptor antagonists (basiliximab) to
recipients with non-donor-specific HLA antibodies (NonDSA) or
no HLA antibodies at all (NoAB). Pre-formed DSA are accepted only
if mean fluorescence intensity (MFI) < 100000 and only if not mul-
tiple DSA > 1000 are present and only if crossmatch negative.
Maintenance immunosuppression consists of a calcineurin inhibi-
tor (cyclosporine or tacrolimus) and an anti-proliferative drug
(mycophenolate mofetil). Target trough levels at 6, 12 and
24 months are 100–160 ng/ml, 80–120 ng/ml, 50–80 ng/ml and
7–10 ng/ml, 6–8 ng/ml, 4–6 ng/ml, for cyclosporine and tacrolimus,
respectively. Steroids are generally withdrawn 6 months post-
transplantation. Kidney biopsies are performed as indication biop-
sies in patients who develop de novo DSA and/or have signs of allo-
graft function deterioration (i.e. increasing creatinine and/or
increasing proteinuria). If antibody-mediated rejection (ABMR) is
present, patients are treated with a steroid bolus, a switch to a
tacrolimus-based triple-immunosuppression and, depending on
acuity and severity, with combinations of IVIG, rituximab, immune
adsorption or plasmapheresis. Detection of de novo DSA without
functional deterioration and without biopsy proven ABMR does
not entail intensification of immunosuppression.
2.3. Stratification into immunological risk groups according to
Luminex results
HLA antibody monitoring using Luminex mix assay (pooled
antigen panel beads with different class I or II HLA antigens, LABSc-
reen Mixed Class I and II antibody screening kit, OneLambda
Canoga Park, CA, USA) is routinely performed at least once a year
or more frequently in case of a deterioration of graft function or
development of proteinuria. If the Luminex mix assay is positive,
an additional Luminex single antigen bead (SAB) assay is per-
formed at least once to specifically test for HLA-A/B/C and HLA-
DRB1, DR51/52/53, DQA1/DQB1 and DPA1/DPB1 antibodies
(LabScreen Single Antigen Beads, OneLambda Inc.). Donor and
recipients were all typed for HLA-A, -B, and -DR and from 2012
onwards also for -DQ). Calculated MFI values are normalized
against the internal negative control and the negative serum con-
trol. If an allele specific antibody against the donor is discovered
in the single antigen Luminex screening assay, it is labeled as a
DSA.
Patients were stratified into immunological risk groups consid-
ering all available pre- and post-transplant anti-HLA-Antibodies
detected by Luminex. The following immunological risk groups
were defined: patients without HLA antibodies (NoAB) or with
HLA antibodies (AB). The AB group was further stratified into
patients with HLA antibodies with donor specificity (DSA) and
patients with HLA antibodies without donor specificity (NonDSA).
To ensure correct patient stratification, patients with inconclusive
data by Luminex assay were excluded from the analysis: i.e.: pos-
itive Luminex mix without verification with Luminex SAB, anti-
body MFI levels < 1000 (i.e. below the cutoff for a positive
Luminex assay according to the Swiss Organ Procurement System),
no Luminex results within 12 months of the most recent follow-up
visit, and positive DQ antibody without DQ locus typing.
2.4. Data analysis and primary outcome
All relevant baseline and outcome data were collected retro-
spectively from electronic medical records. eGFR was calculated
using the Chronic Kidney Disease Epidemiology Collaboration cre-




AKI Acute kidney injury
CI Confidence interval
CNI Calcineurin inhibitor
CKD Chronic kidney disease
CKD-EPI Chronic kidney disease epidemiology collaboration cre-
atinine equation
DD Deceased donor
DSA Donor-specific HLA antibodies
eGFR estimated glomerular filtration rate
LD Living donor
MFI Mean fluorescence intensity
NoAB No HLA antibodies
NonDSA Non-donor-specific HLA antibodies
PRA Panel reactive antibodies
SAB Single antigen bead
TCMR T-cell-mediated rejection
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eGFR slope in the medium post-transplantation period (three-year
slope, months 12–48) between the different immunological risk
groups. The eGFR slope was calculated by linear regression using
all available creatinine measurements. A minimum of three crea-
tinine measurements per time interval were required for the eGFR
slope calculation. eGFR slopes were determined starting at
12 months post-transplantation (baseline; margin ± 2 months)
for different, cumulative time intervals post-transplantation:
months 12–24, 12–36, 12–48, and 12–60, respectively (Suppl.
Fig. 1A–E). Patients with severe acute kidney injury (AKI) requiring
dialysis were completely excluded from the analysis, as creatinine
values during AKI would introduce a relevant bias in slope calcula-
tion. Proteinuria was assessed by protein/creatinine ratio in ran-
dom spot urine measurements.
2.5. Statistics
eGFR slopes were calculated by linear regression using R statis-
tical package. Descriptive statistics of the variables analyzed are
presented as mean ± 95 confidence interval (CI). Independent
groups were compared using Mann Whitney-U test in case of
non-Gaussian data distribution or students T-test if data passed
normality tests (Pearson omnibus). Non-categorical data was com-
pared with chi-square test. For all tests, a p-value of < 0.05 was
considered as statistically significant. Statistical analysis and fig-
ures were done with Graph Pad Prism software.
3. Results
3.1. Study population and immunologic risk groups
From January 2006 to February 2015 a total of 738 patients
received a kidney transplantation at the University hospital of
Zürich. Patient characteristics are presented in Tables 1. Of 416
patients meeting the inclusion criteria 178 patients (42.7%) were
excluded because of insufficient data for eGFR slope calculation
(Fig. 1A). This exclusion ensured uniform groups and robust data
with respect to description of eGFR slope. Median follow-up time
of the remaining 238 patients was 1808 days, i.e. 60 months (25.
percentile 1199 days, 75.percentile 2528 days).
HLA antibodies (AB) were detected in 106 (44%) patients. Out of
these 33 (31%) patients had only non-donor-specific HLA antibod-
ies (NonDSA), whereas 73 (69%) patients had in addition donor-
specific HLA antibodies (DSA). Of note, all of these patients had
DSA and NonDSA, but are referred to the group with DSA through-
out the manuscript. (Fig. 1B). Detection of de novo DSA occurred at
a median time of 1078 days, i.e. 35 months post-transplantation
(95% CI 1063–1614 days) and detection of de novo NonDSA
occurred at a median time of 743 days, i.e. 24 months post-
transplantation (95% CI 624–1472 days).
With respect to the burden of HLA antibodies, there was no dif-
ference between the two groups in the number of HLA antibodies
per individual patient (p = 0.07, data not shown). However, speci-
ficity of HLA antibodies did significantly differ between the two
groups: patients with DSA showed predominance for class II HLA
antibodies (p < 0.0001), while patients with NonDSA only, showed
predominance for class I HLA antibodies (p = 0.0001) (Fig. 1C + D).
3.2. Presence of HLA antibodies is associated with a progressive
deterioration of graft function
One-year kidney allograft function, reflecting the starting point
of the eGFR slope trajectory, was not different among patients with
AB and those with NoAB (Fig. 2A). Over the following periods of
three years (months 12–48) the median eGFR slope was + 0.7 ml/
min/1.73 m2/year in patients with NoAB. In contrast, in patients
Table 1A





Number, n 132 106
Preformed antibodies, n – 52
De novo antibodies, n – 54
Male gender, n (%) 95 (72) 58 (55)
Female gender, n (%) 37 (28) 48 (45)
Age at transplantation, mean years,
(95% CI)
53 (51; 55) 50 (47;52)
Follow up time, median days, (min;
max)
2047 (355; 3405) 1781 (346;
3645)
Detrimental Outcome (%) 6 (0.05) 6 (0.06)
Graf failure 2 1
Death with functioning Graft 4 5
Biopsies (%) 5 (4) 65 (61)




No biopsy (unknown) 127 41
Kidney transplant, n
Living donor transplant (%) 54 (41) 44 (42)
Deceased donor transplant (%) 78 (59) 62 (58)
Donor age deceased donor, years
(95% CI)
53 (50–57) 47 (43–52)
Primary renal disease, n
Glomerulonephritis (%) 29 (22) 27 (25)
Polycystic disease (%) 36 (27) 16 (15)
Urologic disease (%) 6 (5) 6 (6)
Hypertension (%) 17 (13) 6 (6)
Diabetic Nephropathy (%) 8 (6) 4(4)
Other (%) 36 (27) 47 (44)
*One biopsy with TCMR and ABMR.
Table 1B
Groups of patients with HLA antibodies: DSA vs nonDSA.
Group HLA Antibodies (AB)
DSA NonDSA
Number, n 73 33
Preformed antibodies, n (%) 34 (47) 18 (55)
De novo antibodies, n (%) 39 (53) 15 (45)
Male gender, n (%) 35 (48) 23 (70)
Female gender, n (%) 38 (52) 10 (30)
Age at transplantation, mean years, (95 CI) 50 (47;53) 48 (43;53)




Time to de novo antibodies, days (95% CI) 1078 (1063–
1614)
743 (624–1472)
Detrimental Outcome (%) 5 (0.07) 1 (0.03)
Graft failure 1 0
Death with functioning graft 4 1
Biopsies (%) 48 (6) 17 (51)




No biopsy (unknown) 25 16
Kidney transplant
Living donor transplant (%) 33 (45) 11 (33)
Deceased donor transplant (%) 40 (55) 22 (66)
Donor age deceased donor, age (95% CI) 48 (42–53) 47 (40–55)
Primary renal disease
Glomerulonephritis (%) 15 (21) 12 (36)
Polycystic disease (%) 13 (18) 3 (10)
Urologic disease (%) 4 (5) 2 (6)
Hypertension (%) 4 (5) 2 (6)
Diabetic Nephropathy (%) 2(3) 2 (6)
Other (%) 35 (48) 12 (36)
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with AB, the three-year eGFR slope was negative with 1.6 ml/m
in/1.73 m2/year (p = 0.006 as compared to NoAB) (Fig. 2B). This
results in a difference in eGFR slope over three years of 2.3 ml/m
in/1.73 m2/year between patients with antibodies versus without
antibodies (AB vs. NoAB). Consistently, eGFR slope was also posi-
tive for all the other time intervals both for living as well as
deceased allografts with NoAB (Suppl. Fig. 2A) and negative at all
time intervals for patients with AB (Suppl. Fig. 2B).
Important to note, that differences in eGFR slope between the
different immunological risk groups were not due to different
levels of immunosuppression (Suppl. Fig. 3A and B). Furthermore,
despite significant differences in eGFR slopes between the two
groups, levels of proteinuria were not significantly different
between patients with AB and those with NoAB (Suppl. Fig. 3C).
Additionally, graft failure rate over the whole observation period
was not significantly different between the groups (1 graft failure
in AB group, 2 graft failures in NoAB group) (Table 1A).
3.3. Both, DSA and NonDSA negatively impact graft function, however
with a later onset in patients with NonDSA
Subgroup analysis of eGFR in patients with AB stratified in those
with DSA and those with NonDSA confirmed a similar allograft
function at one year post-transplantation (Fig. 2C). Over the next
three years a significantly negative eGFR slope occurred for
patients with DSA as compared to patients with NoAB (eGFR slope
months 12–48 after transplantation: 1.5 ml/min/1.73 m2,
p = 0.015). Similarly, patients with NonDSA also showed a signifi-
cantly negative eGFR slope over three years as compared to
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- 60: combined transplantation
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Fig. 1. Study flow chart A) Study flow chart with patient stratification into two main immunological risk groups: NoAB and AB. B) Further stratification of patients with AB:
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Fig. 2. Baseline eGFR and three-years eGFR slope in patients with different immunological risk groups A) Baseline eGFR at 12 months in patients with NoAB as compared to
patients with AB. B) Three-years eGFR slope (months 12–48) in patients with NoAB as compared to patients with AB. C) Baseline eGFR at 12 months in patients with DSA as
compared to patients with NonDSA and D) Three-years eGFR slope (months 12–48) in patients with DSA and NonDSA as compared to patients with NoAB. Box plots showing
median and 10 and 90. percentile. eGFR slope data is shown as mean ±CI. Group comparison by Mann Whitney U test.
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3 m2/year, p = 0.03) (Fig. 2D). These results remained unchanged
even when including all patients with DSA and NonDSA below
and above MFI threshold 1000 (data not shown). The comparison
of the courses in eGFR changes in yearly time intervals between
patients with NoAB and patients with DSA or NonDSA, showed
development of a negative eGFR slope in patients with DSA already
in the early post-transplantation period, while eGFR slope turned
significantly negative later in patients with NonDSA, i.e. in the
medium-term post-transplantation period (Suppl. Fig. 4). Of note,
eGFR slope was not significantly different in patients with either
pre-formed or de novo DSA or NonDSA, respectively (Suppl. Fig
5A and B). When further differentiating patients with DSA and
NonDSA in those with persistent and intermittently detectable
antibody, results were highly consistent in those with persistently
detectable DSA and NonDSA, but more variable in the other groups
(Suppl. Fig 6A–F).
4. Discussion
Detection of HLA antibodies is associated with deterioration of
renal allograft function as measured by negative eGFR slope over
three years, which reflects the medium follow-up time post-
transplantation. Such functional deterioration is observed irrespec-
tive of donor specificity of HLA antibodies as compared to patients
with no detectable HLA antibodies. Our study is novel in that we
have examined the association between presence of HLA antibod-
ies and eGFR slope, while others have focused on graft failure in
relation to sensitization status. Of note, despite a significant differ-
ence in eGFR slope between different immunological risk groups,
there was no difference in graft failure rates over the whole obser-
vational period in our cohort. This suggests that eGFR slope is more
sensitive in detecting changes in allograft function already at early
time points, while graft loss being a late endpoint. The calculation
of eGFR slope to predict the trajectory of kidney disease progres-
sion has initially been described by Mitch et al. [20] and has
recently been re-adopted and validated as surrogate end point
for progression to kidney failure in CKD trials[21,23] and graft fail-
ure after ABMR[21,23,25] Hence, the National Kidney Foundation
workgroup for establishing early surrogate endpoints of kidney
disease progression recently showed, that a difference in treatment
effects between two treatments of 0.74 ml/min per 1.73 m2/year
mean difference in total eGFR slope over 3 years was associated
with a 97.5% probability of a clinically relevant benefit[21]. Refer-
ring to our observation of a 2.3 ml/min per 1.73 m2/year between
group difference of eGFR slope over 3 years for patients with NoAB
as compared to those with AB, we therefore hypothesize, that our
observation of functional deterioration in patients with AB, irre-
spective of donor specificity, is not only statistically, but also clin-
ically relevant.
While a group from the Mayo clinic reported an average eGFR
slope of 1 ml/min per 1.73 m2/year [26] for the whole cohort
of kidney transplant recipients between year 1 and 5 post-
transplantation, they did not differentiate between different
immunologic risk groups. Yet they state that the majority of
patients showed stable or improving graft function, with only a
subgroup of grafts showing functional deterioration. Consistently,
we observed in our cohort for patients with NoAB an improvement
of allograft function as reflected by a positive eGFR slope. Such
functional improvement in the absence of immunologic tissue
injury could be explained by the kidney’s functional plasticity
(adaptive hyperfiltration), as it is observed after unilateral
nephrectomy in kidney donors [27,28]. Alternatively, it might be
a consequence of the reduction in calcineurin inhibitor dose over
time when allograft function remains stable. In contrast to this
low immunological risk group, we observed a negative slope in
the medium post-transplantation period for both groups with AB,
i.e. DSA and NonDSA. While the association of DSA with functional
allograft deterioration is well known in the literature [2,7,9,29], the
role of NonDSA is debated [13–18]. While some previous studies
with very long follow-up have suggested a negative impact of Non-
DSA on 10-year [13] or longer [17] allograft survival, more recent
studies investigating 5-year allograft survival rates and biopsy pro-
ven ABMR could not detect an effect of NonDSA [15,18]. We
hypothesize, that the analysis of graft function by eGFR slope as
done in our study, might detect more subtle changes induced by
non-donor-specific immune responses leading to graft loss in the
very long-term only, which are unlikely to be captured with 5-
year allograft survival rates and might explain the controversial
results. According to our results, both pre-transplant and de novo
occurrence of NonDSA, especially if persistently detectable by
Luminex, are associated with allograft function deterioration.
From a pathophysiological point of view and based on previous
reports of earlier appearance of NonDSA as compared to DSA [17],
we speculate that detection of NonDSA may reflect inflammatory
tissue injury. Such responses, irrespective of donor specificity,
might be associated with late allograft functional deterioration,
corresponding to chronic allograft nephropathy. Recent studies
investigating the pathophysiology of chronic allograft failure have
indeed shown an important role for natural antibodies, i.e. anti-
bodies reacting to multiple distinct, self and non-self antigens, gen-
erated in the absence of DSA and occurring as a reaction to
ischemia–reperfusion injury [30]. Hence, in this context, NonDSA
might represent a nonspecific marker of ongoing injury and heal-
ing and may be a precursor of later development of donor-
specific alloreactivity contributing to late graft fibrosis and dys-
function, a scenario previously shown in animal work [31].
Our study design reflects the real clinical setting and identifies
associations, however the results do not allow any interpretation
in terms of causality. A major strength of our study is the granular-
ity of data with respect to HLA antibody screening and eGFR slope
analysis, which has recently been evaluated as a surrogate marker
for early detection of end stage renal disease [4,21,23,25]. Consis-
tent annual screening of all the transplant patients in our cohort
was performed over a long follow-up period with HLA antibody
detection by Luminex mix assay and consecutive Luminex SAB
assay if indicated. Integration of these data with longitudinal func-
tional follow-up and calculation of individual eGFR slopes helps to
better understand the natural course of individual allograft func-
tion in the presence or absence of an immunological response,
and might permit early detection of subtle changes and identifica-
tion of ‘at risk’ grafts for late-stage graft loss. Application of strict
criteria regarding patient stratification and eGFR slope calculation
ensured homogenous subgroups and robust data sets, yet it meant
excluding a high percentage of patients. Hence, a bias towards
patient selection cannot be excluded, which is a limitation of our
study. Furthermore, misclassification of some patients is possible
as mixed Luminex assay were not always associated with the
higher sensitivity single antigen detection; neither C, DPA, DPB loci
or high resolution typing were regularly performed. Also, we did
not routinely search for non-HLA antibodies. Moreover, we did
not capture data on cardiovascular risk factorsthat might also
affect eGFR. Lastly, protocol biopsies are not performed in our cen-
ter. Therefore, a correlation of immunological and functional data
with biopsy results was not possible and unfortunately, the group
of special interest, i.e. patients in the NonDSA group with func-
tional deterioration were not biopsied (Suppl. Fig. 7A + B). Hence,
the pathophysiological link remains speculative.
In conclusion, we show that renal allograft function, as assessed
by eGFR slope, declines similarly in the medium-term after trans-
plantation in patients with HLA antibodies, irrespective of donor
specificity. In contrast, allograft function tends to improve in the
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medium-term post-transplantation in patients with no HLA anti-
bodies. Our results therefore contribute to the understanding of
immunological processes after kidney transplantation and support
the clinical relevance of NonDSA with respect to late deterioration
in allograft function.
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